Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 5/20 | 0.39 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.38 |
| ▸ | ABL1 | P00519 | 3/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24737727 | 1.00 | KLKB1 (0.39) | KLKB1METTL3LRRK2ABL1TYK2 | |
| SCHEMBL29137010 | 0.91 | KLKB1 (0.39) | KLKB1METTL3LRRK2ABL1MAP4K1 | |
| SCHEMBL29137006 | 0.91 | KLKB1 (0.39) | KLKB1METTL3LRRK2ABL1MAP4K1 | |
| SCHEMBL29880230 | 0.91 | KLKB1 (0.39) | KLKB1METTL3LRRK2ABL1MAP4K1 | |
| SCHEMBL29302960 | 0.91 | KLKB1 (0.39) | KLKB1METTL3LRRK2ABL1MAP4K1 | |
| SCHEMBL24737893 | 0.87 | KLKB1 (0.36) | KLKB1METTL3LRRK2ABL1TYK2 | |
| SCHEMBL29879716 | 0.87 | KLKB1 (0.36) | KLKB1METTL3LRRK2ABL1TYK2 | |
| SCHEMBL29829825 | 0.86 | KLKB1 (0.35) | KLKB1METTL3LRRK2ABL1TYK2 | |
| SCHEMBL27030047 | 0.86 | KLKB1 (0.35) | KLKB1METTL3LRRK2ABL1TYK2 | |
| SCHEMBL24738308 | 0.85 | KLKB1 (0.39) | KLKB1METTL3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4585265-A2 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2025-07-16 | — | — | EP | disclosed |
| EP-4308230-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |